Rodriguez-Torres, Maribel <br/><br/>
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.  [electronic resource] 

 -  Annals of hepatology   
 - 834-845 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1665-2681 
<br/><br/><label>Standard No.: </label>10.5604/16652681.1222098  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Black or African American<br/>Aged<br/>Antiviral Agents--adverse effects<br/>Biomarkers--blood<br/>Carbamates<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--diagnosis<br/>Hispanic or Latino<br/>Humans<br/>Imidazoles--adverse effects<br/>Interferon-alpha--adverse effects<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--adverse effects<br/>Puerto Rico<br/>Pyrrolidines<br/>RNA, Viral--blood<br/>Recombinant Proteins--adverse effects<br/>Ribavirin--adverse effects<br/>Time Factors<br/>Treatment Outcome<br/>United States--epidemiology<br/>Valine--analogs & derivatives<br/>Viral Load<br/>Young Adult